Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 14;4(12 Suppl Anatomy and Safety in Cosmetic Medicine: Cosmetic Bootcamp):e1155.
doi: 10.1097/GOX.0000000000001155. eCollection 2016 Dec.

Noninvasive Submental Fat Compartment Treatment

Ava T Shamban  1
Affiliations

Noninvasive Submental Fat Compartment Treatment

Ava T Shamban. Plast Reconstr Surg Glob Open. .

Abstract

Background: KYBELLA, ATX-101, is an injectable form of sodium deoxycholic acid. It is currently the only Food and Drug Administration-approved injectable drug for the reduction of submental fat.

Objectives: A literature review and discussion of the treatment of submental fat.

Results: KYBELLA is a well-tolerated alternative for the treatment of submental fat.

Conclusions: KYBELLA is a safe and efficacious, first in class, injectable drug for the reduction of submental fat.

PubMed Disclaimer

Conflict of interest statement

The author has no financial interest to declare in relation to the content of this article. The Article Processing Charge for this proceeding was paid for by Allergan plc, as part of an unrestricted educational grant to support the entire Cosmetic Boot Camp 2016 Supplement. Allergan plc had no involvement in the production, selection, or review of this proceeding supplement.

Figures

Fig. 1.
Fig. 1.
Site results of 4 consecutive treatments consisting of 4 mL of KYBELLA once every 30 days. Before treatment (A) and after treatment (B). Photograph is used with patient consent.
Fig. 2.
Fig. 2.
Site results of 6 KYBELLA treatments, 4 mL treatments spaced 30 days apart. Before treatment (A) and after treatment (B). Photograph is used with patient consent.
Fig. 3.
Fig. 3.
Landmarks for injections with KYBELLA. Reprinted with permission from Allergan plc.
Fig. 4.
Fig. 4.
Postplatysmal fat. Reprinted with permission from Allergan plc.
Fig. 5.
Fig. 5.
Anterior view of the preplatysmal fat. Reprinted with permission from Allergan plc.
Fig. 6.
Fig. 6.
Treatment area. Reprinted with permission from Allergan plc.
See this image and copyright information in PMC

References

    1. Jones DH, Carruthers J, Joseph JH, et al. REFINE-1, a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial with ATX-101, an injectable drug for submental fat reduction. Dermatol Surg. 2016;42:38–49. - PubMed
    1. Duncan D, Rotunda AM. Injectable therapies for localized fat loss: state of the art, clinics in plastic surgery. Clin Plast Surg. 2011;38:489–501. - PubMed
    1. Beer K, Donofrio L, Gross TM, et al. Clinically meaningful reduction in submental fat during and after treatment with ATX-101 in the US/CAN phase 3 trials, REFINE-1, and REFINE-2. Presented at 73rd Annual Meeting of the American Academy of Dermatology; March 20–24, 2015; San Francisco, CA.
    1. Coleman SR, Grover R. The anatomy of the aging face: volume loss and changes in 3-dimensional topography. Aesthet Surg J. 2006;26(1S):S4–S9. - PubMed
    1. Ascher B, Hoffmann K, Walker P, et al. Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study. J Eur Acad Dermatol Venereol. 2014;28:1707–1715. - PMC - PubMed